Exelixis, Inc. — Form 10-Q Summary
Period and source note: The filing covers the quarter ended April 1, 2022 (financial statements presented as of and for the three months ended March 31, 2022) and was signed May 10, 2022. This conflicts with the request metadata identifying 2021 Q1. The supplied text also refers to events in May and June 2022, after the stated signature date; verify the original filing and chronology.
Business context
Exelixis is an oncology-focused biotechnology company. Cabozantinib products, primarily CABOMETYX, generated most revenue. The company also earns collaboration and licensing revenue and is advancing a pipeline that includes XL092, XB002, XL102 and XL114.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 | Change / context |
|---|---|---|---|
| Total revenue | $356.0 million | $270.2 million | Up 32% |
| Net product revenue | $310.3 million | $227.2 million | Up 37%; CABOMETYX revenue rose 35% to $302.8 million |
| License revenue | $32.1 million | $27.5 million | Up 16% |
| Collaboration services revenue | $13.6 million | $15.5 million | Down 12% |
| Operating income (loss) | $83.2 million | $(4.6) million | Turned profitable |
| Net income | $68.6 million | $1.6 million | Diluted EPS $0.21 versus $0.00 |
| Gross margin | 96% | 94% | As reported by the company |
| Operating cash flow | $147.7 million | $39.5 million | Higher collections, including a $100 million Ipsen milestone |
Operating expenses were $272.7 million, compared with $274.8 million. R&D was $156.7 million versus $159.3 million; SG&A was $102.9 million versus $102.4 million. At March 31, cash, cash equivalents, restricted cash equivalents and investments totaled $1.989 billion; working capital was $1.554 billion. Total liabilities were $360.3 million, and no borrowings are separately reported in the supplied balance sheet. Cash and investments increased from $1.855 billion at December 31, 2021. Investing activities used $74.5 million; financing activities provided $0.2 million.
Changes and drivers
- Product-revenue growth primarily reflected a 33% increase in CABOMETYX units sold, following approval with OPDIVO as first-line treatment for advanced RCC, and a 2% increase in average net selling price.
- Discounts and allowances increased 59% to $137.9 million, driven mainly by higher 340B and Medicaid utilization and co-pay assistance. The company expects discounts as a share of gross sales may continue to rise.
- License revenue benefited from increased cabozantinib royalties from Ipsen and Takeda. Collaboration services revenue reflected lower development-cost reimbursements.
- R&D expense was lower mainly because of reduced licensing and collaboration costs, stock compensation and certain trial costs. SG&A was broadly stable as personnel and marketing costs were offset by lower stock compensation.
- Other comprehensive loss included $5.9 million of unrealized losses on available-for-sale debt securities, which management attributed primarily to interest-rate and market-liquidity movements, not credit risk.
Outlook, commentary and risks
- No numerical full-year revenue or earnings guidance is provided. Management said net product revenue may increase during the remainder of 2022; R&D and SG&A may rise, collaboration services revenue may decline, and gross margin is expected to remain broadly stable.
- Management expects available liquidity and anticipated product and collaboration revenue to fund operations for at least 12 months after filing. It also expects operating cash requirements to increase and may consider debt or equity financing for growth or strategic reasons.
- For COSMIC-312 in previously untreated advanced HCC, the final overall-survival analysis showed neither improvement nor detriment for cabozantinib plus atezolizumab versus sorafenib; the company said it did not intend to submit an sNDA for the combination.
- Development outlook included expected COSMIC-313 top-line results in July 2022, interim results from CONTACT-01 and CONTACT-03 in the second half of 2022, and plans to begin a global Phase 3 XL092 trial. These are forward-looking expectations, not reported outcomes.
- Key risks include dependence on CABOMETYX, clinical-trial and regulatory uncertainty, pricing and reimbursement pressure, competition, reliance on collaboration partners, and potential generic entry. MSN and Teva had filed challenges related to generic CABOMETYX; the company warned early generic competition could materially reduce U.S. revenue. The MSN cases were ongoing, and the Teva case was stayed.
- COVID-19 was described as having a modest operational impact at the time, but further disruption could delay trials or affect revenue. The filing also identifies possible clinical-operational effects from the Russo-Ukrainian war and inflationary cost pressures.
- A new approximately 220,000-square-foot Alameda office building was substantially completed in April 2022. The lease term is 242 months, with extension options and a termination option after 180 months.
Most important facts to verify
- Confirm whether the requested period should be Q1 2021 or Q1 2022, and reconcile the filing’s stated period-end and signature date with the supplied references to later 2022 events.
- Check the original filing for the precise status and expected timing of the MSN and Teva patent litigation and any subsequent generic-entry developments.
- Validate the revenue-growth drivers against CABOMETYX volume, pricing, gross-to-net discounts and payer mix, particularly the rising discount and rebate burden.
- Track clinical readouts and regulatory decisions for COSMIC-313, CONTACT studies and XL092; distinguish reported results from management expectations.
- Review the full-year expense trajectory, liquidity deployment and new lease commitments against management’s stated outlook.